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INTRODUCTION
TheMr 190,000multidrug resistance protein (MRP)1
is an identified member of the ATP-binding cassette
(ABC) transmembrane transport proteins (1). In ad-
dition to the glioma cell lines (T98G and Gli36) from
which these proteins were isolated, overexpression
of MRP1 has been detected in many multidrug resis-
tant tumor cell lines derived from various tissues and
selected in different natural product type chemothera-
peutic agents (2).
The efficacy of topoisomeraseⅡ inhibitors (e.g.,
epipodophyllotoxins, aminoacridine, and mitoxan-
trone) is limited by the occurrence of drug resistance
in the tumor cell population. Cellular insensitivity to
drugs that stabilize the cleavable complex is frequently
expressed as multidrug resistance (MDR)(2). In some
cell lines, overexpression of MDR-1/P-glycoprotein
or the multidrug resistance associated protein (MRP)
1-5, has beendemonstratedand implicatedas themecha-
nism of resistance(2, 3). These proteins are known to
confer multidrug resistant phenotypes to the cancer
cells. Although the primary structuresof P-glycoprotein
andMRP share only 15% amino acid homology (1), both
P-glycoprotein andMRP are involved in the drug re-
sistance to a similar profile of chemotherapeutic agents
that include anthracyclines, vinka alkaloid, and epipo-
dophyllotoxins (3). Another transporter, termed breast
cancer-resistance protein (BCRP), also known as
Mitoxantrone-resistance protein and placenta ABC
protein, was described in breast and colon carcinoma
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cell lines selected for higher-level resistance to the an-
tineoplastic drug, Mitoxantrone (3).
The cells that overexpress P-glycoprotein may be
sensitized to the cytotoxic effects of chemotherapeutic
agents by the co-administration of a wide variety of
the so-called “reversing agents”(4). Two of the most
extensively studied reversing agents both in vitro and
in vivo are verapamil, a calcium channel blocker, and
cyclosporin A, an immunosuppressive cyclic peptide.
However, both verapamil andcyclosporinAare relatively
ineffective and/or non-specific chemosensitizers inMRP
expressing cell lines, promoting a search for alterna-
tive ways to reverse theMRP1-mediated resistance (4).
One particularly attractive approach is to use antisense
oligonucleotides, because of the potentiallyhighdegree
of specificity of these reagents. Rather than inhibiting
the protein function, the antisense oligonucleotides
decrease mRNA and protein synthesis by binding to
its complementary nucleic acid target in a sequence
specific manner (5-7).
This study demonstrates that the antisense oligonu-
cleotides can increase the sensitivity of the tumor cells
to the anticancer drugs by decreasing the expression





The oligonucleotides used in this studywas described
previously (7). The oligonucleotides was 20 bases in
length and was phosphorothioate oligodeoxynucleo-
tides. The sequences of antisense oligonucleotides for
the MRP1 was as follows : 21075’-TGCTGTTCGTGCC
CCCGCCG-3’
Cell culture and treatment
The T98G-VP and Gli36-VP aremultidrug resistant
human glioma cell lines overexpressing theMRP,which
were derived from the parental T98G and Gli36 cells
by culture in etoposide (VP-16)(8).
These cells were grown in 75cm2 flasks until 70-80%
confluent and then were washed twice with serum-free
MEMmedium before the addition of lipofectin/oli-
gonucleotide complexes. Lipofectin (GIBCO/BRL life
technologies, Burlington, Ontario, Canada)(10µg/ml)
and the oligonucleotideswere allowed to formcomplexes
in serum-free MEMmedium at room temperature for
15 min after gentle mixing. The cells were incubated
with lipofectin/oligonucleotide at 37℃ for 4hr, washed
once with MEM/10% fetal bovine serum, and then
incubated in fresh MEM/10% fetal bovine serum
until harvested.
Reverse transcription and polymerase chain reaction
(PCR) analysis for the expression of the MRP 1
Total RNAwas isolated from cells by IsogenR (Nippon
gene) according to the manufacture’s instructions.
RT-PCR was performed using First-Strand cDNA Syn-
thesis KitR (Amersham pharmacia biotech). 1 µg of
total RNA was added to 14µl of RT-mixture. Aftermix-
ing, the samples were incubated at 37℃ for 45min,
95℃ for 5 min and 4℃ for at least 5min. 35µl of PCR-
mixture containing 10nM primers and Taq DNA po-
lymerase (Amersham pharmacia biotech) was added
to RT-products. Initial denaturation for 2 min at 94℃
was followed by 30 cycles of 1 min at 94℃, 1 min at
55℃ and 2 min at 72℃ and a final extension for 10min
at 72℃. The PCR-products were separated on 2% aga-
rose gels, and stained with ethidium (9).




Immunoblotting for the theMRP1 was performed
using detergent-solubilizedmembraneproteins resolved
on a 6% SDS-polyacrylamide. Immunoblotting was
performed with a1 : 2000 dilution of amonoclonalMRP1
antibody, kindly provided by Dr. Rik Scheper (Free
University Hospital, Netherlands). After three washes
in TBS-T, the membranes were incubated with HRP-
conjugated anti-mouse secondary antibody at a dilution
of 1:1000 for 1 hr. Five washeswere thenperformedand
immunolabeled protein was detected by chemilumi-
nescence(2).
Cellular Accumulation for[3H]-VP-16
3.5×105 cells were plated in each well of a six-well
plate and incubated for 24 hr at 37℃. Growthmedium
was then replacedwith serum-freeMEM, and the cells
were incubatedwith 2.6µM[3H]-VP 16 for various times
up to 90 min. at 37℃. At the completion of the incuba-
tion period, cells were quickly washed three times with
ice-cold PBS, lysed with 2ml of 0.05% SDS, and mixed
with 3ml of Scintisol (2, 10).Dataderived from thedrug
accumulation analysis was compared using ANOVA.
A probability value of less than 0.05 was accepted as
statistically significant (2).
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Cloning of topoisomerase IIα, MRP1-5, and MDR-1
cDNA by Reverse Transcription-PCR(2)
Synthetic oligonucleotides corresponding to the
published cDNA sequence of human MRP1-5were
used to isolate by RT-PCR specific products for direct
cloning into pGEM-3 z vectors (Promega, Madison,
WI). The identity of the cDNA clones was confirmed
by direct sequenceanalysis prior to their use asprobes for
northern analysis. Thesequencesof the oligonucleotides
used in the RT-PCR were as follows: topoisomerase
IIα : -91 5‘TGTGGAGAAGCGGCTTGGTC 3 ’ and
449 5‘TAGTTACTAGAAGTTAGGAGCT 3’ ; MRP
1 : 733 5 ‘CGGAAACCATCCACGACCCTAATCC
3’ and 1027 5 ‘ACCTCCTCATTCGCATCCACCTTGG3’;
MRP 2 : 4136 5‘CTGCCTCTTCAGAATCTTAG’ and
4376 5‘CCCAAGTTGCAGGCTGGCC’ ; MRP 3 : 5
‘GATACGCTCGCCACAGTCC3’ and 5‘CAGTTGG
CCGTGATGTggCTG 3’ ; MRP 4 : 5‘CCATTGAAG
ATCTTCCTGG3’ and 5‘GGTGTTCAATCTGTGTGC
3’ ; MRP 5 : 5‘GGATAACTTCTCAGTGGG 3’and 5
‘GGAATGGCAATGCTCTAAAG 3’ ; MDR-1 : 352
5‘CAGTGTTTGCCATAGTATTTTCAAGGATTG 3’
and 741 5‘CCCTTTAACACTAGAAGCATCAC 3’.
Northern Blotting
Total RNA(20µg/lane) was separated on a 6% for-
maldehyde gel and transferred to Hybond N＋ with
10 X SSC. The membranes were hybridized at 42℃
overnight with the radiolabeled probe in Hybrisol
I (Oncor, Gaithersburg, MD)2. We used the RNA of
ZR-VP 13that overexpressed all drug resistant genes
(MDR-1, MRP 1-5, topoisomerase Ⅱ α) as positive
control (2).
Cytotoxicity Assays
Cytotoxicity assays were performed as previously
described (11). Briefly, cells were plated at 10000 per
well in 96-well microtiter plates with various concen-
trations of the anticancer drugs〔VP-16, adriamycin, vin-
cristine, cisplatin, and1-(4-amino-2-methyl-5-pyrimidinyl)
methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU)〕and
were cultured for 2 days. Then the cells were incu-
bated with 0.2 mg/ml of MTT in MEM for 4 hr, and
the formazan product wasdissolved indimethyl sulfoxide
and its absorbance at 540 nmwas measured. The cy-
totoxic effects of the drugswereexpressedquantitatively
as the dose required to kill 50% of the cells (IC50).
RESULTS
Table1 depicts the cross-resistance profile of the
two sublines to various chemotherapeutic agents. Cross-
resistance to two topoisomeraseⅡpoisons (VP-16,
adriamycin) was observed in these drug resistant cells
with little cross resistant to non-topoisomerase Ⅱ
poisons, Vincristine, cisplatin, and ACNU. Resistant
sublines treated with theMRP1 antisense oligonucleo-
tide displayed an enhanced sensitivity to topoisomerase
Ⅱ inhibitors, VP-16 and Adriamycin.
When expressions of topoisomerase IIα, MRP1-5,
and MDR-1 were examined, the results shown in Fig.1
and Table2 were obtained. Northern analysis showed
that these resistant cells the overexpress MRP1, but
do notoverexpressMDR-1orMRP1-5except1.Moreover,
in the results of northern blot analysis of mRNA for
topoisomerase IIα and topoisomeraseⅡ activity in
decatanation assay using kinetoplast DNA (data not
shown), identical results are observed in parental
cell lines and their resistant cell lines, suggesting
that alterations in topoisomerase II do not account
for the resistance in these cells.
The VP-16 accumulation study was carried out in
the parental cell lines and their drug resistant sublines
(Fig.2). Figure 2 demonstrates the3 H-VP-16 accu-
mulation in the parental cells and the drug resistant
sublines. Accumulation over 45min. period is displayed
as p mol of VP-16/107cells. 3H-VP-16 accumulations
for the resistant sublines relative to parental cells were
T 98 G-VP, 48% and gli 36-VP, 58%. Increased accumu-
lation was observed in the two resistant sublines treated
with theMRP1 antisense oligonucleotide, with partial
restoration of levels to that of the parental cells (T98
G-VP with MRP1 antisense treatment, 96% of parental
T 98 G ; and Gli36-VP with theMRP1 antisense treat-
ment, 94% of parental Gli 36).
Figure 3 depicts concentration-dependent reduction
of MRP1 mRNA and protein in VP-16 resistant cell lines
by a treatment with theMRP1 antisense oligonucleotide.
The T98G-VP and Gli-VP cells were exposed for 4 hr
to selected concentrations of the MRP1 antisense oli-
gonucleotide. The MRP1 mRNA was isolated24hr
after treatment, and RT-PCR and immunoblotting were
performed. A concentration-dependent decrease in
the MRP1 mRNAwas observed after a single treatment
of the T98G-VPwith theMRP antisense oligonucleotide.
A significant decrease of the MRPmRNA and protein
were observed at 0.1µM, and virtually noMRPmRNA
was detectable at oligonucleotide concentration of
0.3 µM (upper panel). Similar results were found in
the experiment using theGli36-VP cell line. Significant
reduced MRP mRNA and protein were detectable at
oligonucleotide concentration of 0.3µM (lower panel).
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Figure 1：Northern blot analysis of topoisomerase IIα(4.5 KB), MRP 1-5(4.5 KB, 4.4 KB, 4.7 KB,
4.3 KB, 6.5 KB), and MDR-1 (4.5 KB) expression in drug resistant sublines and their parental
cell lines. The RNA of ZR-VP13 that overexpressed all drug resistant genes (MDR-1, MRP 1-5,
topoisomerase Ⅱ α) was used as positive control. β-actin was used as internal control.
Figure 2 : VP-16 accumulation study was carried out in parental cell lines and their drug resistant sublines (A; T98G, B; Gli36).
* significantly different (p<0.05) between resistant cell lines and their parental cell lines(incubation time at 45 min).
* * significantly different (p<0.05) between resistant cell lines and their own transfected MRP 2 antisense cDNA (incubation
time at 45 min)
left panel : ■ ; T98G, ● ; T98G-VP, ◇ ; T98G-VP with MRP 1 antisense treatment
right panel : ★ ; Gli 36,▼ ; Gli 36-VP, △ ; Gli 36-VP with MRP 1 antisense treatment
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Figure 3 : Concentration-dependent reduction of MRP1 mRNA and protein in etoposide resistant cell lines by a treatment with
the MRP1 antisense oligonucleotide. Upper panel;a concentration-dependent decrease in the MRP1 mRNA and protein were
observed after a single treatment of T98G-VP and Gli 36-VP with MRP antisense oligonucleotides.
Table 1. Cross resistace profile of the drug resistant cell lines
1）Gli３６-VP
IC50 IC50 ratioa IC50 ratioa
Gli 36 Gli-VP(-)b Gli-VP(-)Gli 36 Gli-VP(+)
c Gli-VP(+)
Gli 36
VP 16d 1.5±0.4 37.5±3.5 25 2.5±1.2 1.7
ADMe 0.031±0.01 0.37±0.08 12 0.043±0.22 1.4
VCRf 0.31±0.13 0.39±0.21 1.3 0.29±0.16 0.9
CDDPg 220±55 290±78 1.3 310±98 1.4
ACNUh 420±120 480±140 1.1 450±100 1.1
IC50 : ng/ml
2）T98G-VP
IC50 IC50 ratioa IC50 ratioa
T98G T98G-VP(-)b T98G-VP(-)T98G T98G-VP(+)
c T98G-VP(+)
T９８G
VP 16d 7.5±2.4 137.5±33.5 18 8.5±5.2 1.1
ADMe 0.081±0.01 0.47±0.08 6 0.096±0.02 1.2
VCRf 1.31±0.33 1.39±0.51 1.1 1.39±0.36 1.1
CDDPg 420±155 490±178 1.2 510±198 1.2
ACNUh 390±220 480±140 1.2 450±178 1.2
IC50 : ng/ml
a : ratio of the individual cell lines
b : without MRP antisense oligonucleotides
c : with MRP antisense oligonucleotides
d : etoposide, e : adriamycin, f : vincristine, g : cispatin, h : 1-(4-aminio-2-methyl-5-pyrimidinyl) methyl-3-(2-choloroethyl)-
3-nitrosourea
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DISCUSSION
Since the development of MDR by cancer cells still
represents one of the major reasons for anticancer
chemotherapy failure (12-18), the aim of the present
study was to attemptmodulation and eventually reversal
of MDR in the glioma cell lines in vitro, using antisense
oligonucleotides to targeted to the MRP1 mRNA. In
a previous study, the 16 oligonucleotideswere screened
initially for their ability to decrease theMRP1 protein
and mRNA levels in MRP1-overexpressing H69AR
cells (7). One of the oligonucleotides,whichweused in
this study, was complementary to nucleotide 2107-
2126 of MRP1 mRNA and reproducibly the most ef-
fective in lowering theMRP1 protein andmRNA levels.
It was also demonstrated that the decrease inMRP1
mRNA results from site specific cleavage, consistent
with an RNAseH-dependent antisense mechanism
(10, 19-21).
The ability of MRP1 antisense oligonucleotide to
increase VP-16 cytotoxicity in the T98G-VP andGli36-
VP cells and thus to reverse theMDR was assessed
in combination experiments in which the T98G-VP
and Gli36-VP cells were first exposed toMRPantisense
oligonucleotide and then to VP-16. Treatment with VP-
16 alone had modest effects on the T98G-VP and Gli
36-VP cell proliferation. The in vitro restoration of VP-
16 sensitivity in T98 G-VP and Gli36-VPwas confirmed
by the VP-16 IC50 value for each treatment. A strong
decrease of the IC50 value was observed in the T98G-
VP and Gli36-VP cells treatedwith combination ofMRP
antisense oligonucleotideplusVP-16.Noteworthy, theIC50
value of the resistant cells exposed to antisense oli-
gonucleotide plus VP-16 was essentially identical to that
of the T98G andGli 36 parental cells exposed to thedrug
alone, consistent with a complete restoration of the
VP-16 accumulation in T98G-VP and Gli36-VP cells.
TransfectionexperimentswithMRPexpression vectors
have shown thatMRPcanconfer resistance to adriamycin
and VP-16(22). It hasbeenshown thatMRPgeneencodes
glutathione S-conjugate export carrier, and that the
molecules which are transported byMRP include adria-
mycin glutathione conjugates and glucuronosyl VP-16.
These reports are consistent with our present study
using the MRP antisense oligonucleotide.
MRP expression has also been observed in other
clinical cancers, including colorectal carcinoma, lung
cancer, lung cancer, breast carcinoma, retinoblastoma,
and acute leukemia. Regarding the nervous system,
it has been reported that MRPmRNA and protein are
not detectable in the brain, and glioma cell lines with
higher MRPmRNA levels show increased drug resis-
tance. Since all the present clinical specimens examined
were primary tumors, we considered that the MRP
expression was concerned with intrinsic drug resis-
tance as well as acquired drug resistance (19, 22). In
an attempt to correlate the anti-proliferative effect of
the MRP1 antisense oligonucleotide with the levels
of MRP1 mRNA, we evaluated theMRP1mRNA and
protein expression by RT-PCR and immunoblotting
in the T98G-VP and Gli36-VP cells immediately after
treatment withMRP1 antisense oligonucleotide plus
VP-16. In comparison to the untreated cells, the cells
treated with theMRP1 antisense oligonucleotide ex-
hibited a marked reduction of the MRP1mRNA and
protein. The level of β-actin mRNA were essentially
unchanged in the cells receiving different treatments,
confirming the specificity of the effects induced by
the MRP1 antisense oligonucleotide.
In conclusion, our studies raise the possibility that
antisense oligonucleotide targeted toMRP1 mRNA
might be useful in the attempt to reverse the MDR
in the cancer patients.
Table 2. Northern blot analysis of topoisomerase IIα, MRP1-5, and MDR-1 expression in drug resistant sublines and their parental
cell lines
ZR-VP13 T98G T98G-VP Gli36 Gli36-VP
Topo Ⅱ α 100 114 108 107 112
MRP-1 100 3 105 8 117
MRPP-2 100 8 4 9 10
MRP-3 100 11 9 16 18
MRP-4 100 12 13 18 19
MRP-5 100 12 14 19 20
MDR-1 100 11 9 16 18
Densitometric quantitations of drug resistance gene expressions were performed by comparing with those in ZR-VP13 cells
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